- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Pharmacological effects are due to the combined effect of the components that make up the preparation CYTOFLAVIN®.
CYTOFLAVIN® promotes activation of the aerobic metabolism of cells, which leads to an increase in the level of glucose utilization, contributes to an increased level of beta-oxidation of fatty acids and resynthesis of γ-aminobutyric acid in neurons.
CYTOFLAVIN® increases the resistance of the membranes of nerve and glial cells to the effects of ischemia, which is reflected in a decrease in the concentration of neurospecific proteins that characterize the level of destruction of the main structural components of the nervous tissue.
CYTOFLAVIN® improves coronary and cerebral blood flow, activates metabolic processes in the central nervous system, restores impaired consciousness, promotes regression of neurological symptoms and improvement of cognitive functions of the brain. It has a quick awakening effect in post-anesthetic depression of consciousness.
When using the drug CYTOFLAVIN® in the first 12 hours from the onset of stroke, there is a favorable course of ischemic and necrotic processes in the affected area (reduction of the focus), restoration of neurological status and reduction in the level of disability in the long-term period.
Cytoflavin has high bioavailability.
When taken orally, succinic acid from the gastrointestinal tract enters the blood and tissues, participating in energy metabolism reactions, and completely decomposes to the final metabolic products (carbon dioxide and water) after 30 minutes.
Inosine is well absorbed from the gastrointestinal tract. The time to reach the maximum blood concentration is 5 hours, the average retention time in the blood is 5.5 hours, the equilibrium volume of distribution is about 20 liters. Inosine is metabolized in the liver to form inosine monophosphate, followed by its oxidation to uric acid. In small quantities excreted by the kidneys.
Nicotinamide is rapidly distributed in all tissues (the equilibrium volume of distribution is about 500 liters). The time to reach the maximum blood concentration is 2 hours, the average retention time in the blood is 4.5 hours. Nicotinamide passes through the placenta and into breast milk; metabolized in the liver to form N-methylnicotinamide, excreted by the kidneys.
Riboflavin is rapidly absorbed from the gastrointestinal tract, is distributed unevenly (the largest amount in the myocardium, liver, kidneys), is transformed into flavivainin mononucleotide (FMN) and flavivina din dinucleotide (FAD) in mitochondria. Penetrates through the placenta and into breast milk; excreted by the kidneys, mainly in the form of metabolites.
In adults in complex therapy:
1. Acute cerebrovascular accident.
2. Consequences of cerebrovascular diseases (consequences of cerebral infarction, cerebral atherosclerosis).
3. Toxic and hypoxic encephalopathy in acute and chronic poisoning, endotoxicosis, post-anesthetic depression of consciousness, as well as for the prevention and treatment of hypoxic encephalopathy during cardiac surgery using cardiopulmonary bypass.
In children (including premature with a gestational age of 28-36 weeks) in the complex therapy in the neonatal period:
1. With cerebral ischemia.
1 tablet contains:
active substances: succinic acid - 0.3 g; Riboxin (inosine) - 0.05 g; Nicotinamide - 0.025 g;
Riboflavin mononucleotide (riboflavin) - 0.005 g;
Excipients: polyvinylpyrrolidone of medium molecular weight (povidone), calcium stearate, methacrylic acid-ethyl acrylate copolymer, 1,2-propylene glycol, acid red 2С, Tropeolin O.
No customer reviews for the moment.